- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Lyell Immunopharma pops on recent ASH data, immunotherapy expansion | 4 | Seeking Alpha | ||
| 07.12.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln | |||||
| 05.12.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Lyell Immunopharma reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 10.11.25 | Lyell Immunopharma buys exclusive global rights to colorectal cancer drug | 1 | Seeking Alpha | ||
| 10.11.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer | 104 | GlobeNewswire (Europe) | LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal... ► Artikel lesen | |
| 10.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.11.25 | Lyell Immunopharma: Vielversprechende Daten zu dualer CAR-T-Zelltherapie bei Lymphomen | 1 | Investing.com Deutsch | ||
| 03.11.25 | Lyell Immunopharma, Inc: Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition | 2 | GlobeNewswire (USA) | ||
| 03.11.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.09.25 | Lucid Capital Markets initiates Lyell Immunopharma stock with Buy rating | 2 | Investing.com | ||
| 16.09.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08.25 | Lyell Immunopharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 | 377 | GlobeNewswire (Europe) | Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE... ► Artikel lesen | |
| 12.08.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.07.25 | Lyell Immunopharma announces up to $100 million equity private placement | 1 | Seeking Alpha | ||
| 25.07.25 | Lyell Immunopharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07.25 | Lyell Immunopharma, Inc: Lyell Immunopharma Announces up to $100 Million Equity Private Placement | 3 | GlobeNewswire (USA) | ||
| 18.07.25 | Lyell Immunopharma registers 625,000 shares for resale | 1 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,026 | -14,00 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| AMGEN | 282,35 | -0,04 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| BIOGEN | 156,95 | +0,42 % | Biogen Inc.: Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China | ||
| EDITAS MEDICINE | 1,844 | +0,49 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GALAPAGOS NV | 27,820 | 0,00 % | Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities | Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has... ► Artikel lesen | |
| IMMATICS | 8,185 | -0,12 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| AUTOLUS THERAPEUTICS | 1,730 | +0,58 % | Cellares Corp: Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL (obe-cel) on the Cellares Cell ShuttleTM Platform | Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage... ► Artikel lesen | |
| IGM BIOSCIENCES | 1,080 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 14.08.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 14.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 14.08.2025.ISIN NameCA87168M1068 SYNEX... ► Artikel lesen | |
| TANGO THERAPEUTICS | 9,670 | +8,53 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| TSCAN THERAPEUTICS | 1,140 | +8,57 % | TScan Therapeutics, Inc.: TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition | Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up... ► Artikel lesen | |
| ALUMIS | 16,250 | 0,00 % | Alumis kündigt Aktienemission im Wert von 175 Millionen US-Dollar an | ||
| APOGEE THERAPEUTICS | 78,25 | +0,95 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,120 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| ARCELLX | 62,06 | 0,00 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| RECURSION PHARMACEUTICALS | 4,550 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline |
Das Unternehmen LYELL IMMUNOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,16 % bei einem Aktienkurs von 25,870 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYELL IMMUNOPHARMA INC finden Sie auf Wallstreet Online.